DK1407787T3 - Fremgangsmåde til fremme af nukleinsyreoverförsel - Google Patents

Fremgangsmåde til fremme af nukleinsyreoverförsel

Info

Publication number
DK1407787T3
DK1407787T3 DK02741206T DK02741206T DK1407787T3 DK 1407787 T3 DK1407787 T3 DK 1407787T3 DK 02741206 T DK02741206 T DK 02741206T DK 02741206 T DK02741206 T DK 02741206T DK 1407787 T3 DK1407787 T3 DK 1407787T3
Authority
DK
Denmark
Prior art keywords
nucleic acid
cells
complex particles
gene
protein
Prior art date
Application number
DK02741206T
Other languages
Danish (da)
English (en)
Inventor
Masaaki Terada
Takahiro Ochiya
Yu Aso
Kimi Honma
Akihiko Sano
Shunji Nagahara
Original Assignee
Dainippon Sumitomo Pharma Co
Koken Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dainippon Sumitomo Pharma Co, Koken Kk filed Critical Dainippon Sumitomo Pharma Co
Application granted granted Critical
Publication of DK1407787T3 publication Critical patent/DK1407787T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6435—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a connective tissue peptide, e.g. collagen, fibronectin or gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK02741206T 2001-06-20 2002-06-20 Fremgangsmåde til fremme af nukleinsyreoverförsel DK1407787T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2001186320 2001-06-20
JP2001278293 2001-09-13
PCT/JP2002/006137 WO2003000297A1 (fr) 2001-06-20 2002-06-20 Procede facilitant le transfert d'acides nucleiques

Publications (1)

Publication Number Publication Date
DK1407787T3 true DK1407787T3 (da) 2009-06-02

Family

ID=26617260

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02741206T DK1407787T3 (da) 2001-06-20 2002-06-20 Fremgangsmåde til fremme af nukleinsyreoverförsel

Country Status (12)

Country Link
US (2) US8742091B2 (zh)
EP (1) EP1407787B1 (zh)
JP (1) JP4081436B2 (zh)
KR (1) KR100888566B1 (zh)
CN (1) CN1313158C (zh)
AT (1) ATE429930T1 (zh)
CA (1) CA2451603C (zh)
DE (1) DE60232149D1 (zh)
DK (1) DK1407787T3 (zh)
ES (1) ES2324525T3 (zh)
PT (1) PT1407787E (zh)
WO (1) WO2003000297A1 (zh)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001264317A1 (en) * 2000-06-20 2002-01-02 Koken Co., Ltd. Preparations for oligonucleotide transfer
DE60232149D1 (de) 2001-06-20 2009-06-10 Dainippon Sumitomo Pharma Co Verfahren zur förderung des nukleinsäuretransfers
JP4954550B2 (ja) * 2003-12-19 2012-06-20 大日本住友製薬株式会社 新規な核酸導入法
EP1715052A4 (en) * 2004-01-29 2007-10-03 Nat Inst Of Advanced Ind Scien COMPOSITION AND METHOD FOR INCREASING GENTRANSFER EFFICIENCY
JP2007267602A (ja) * 2004-06-25 2007-10-18 National Institute Of Advanced Industrial & Technology 固相上で細胞に核酸を導入し、かつ、この細胞を分化誘導させるための方法および組成物
JP4585242B2 (ja) * 2004-06-29 2010-11-24 株式会社高研 核酸導入用セルトランスフェクションアレイ
US20090062184A1 (en) * 2005-03-24 2009-03-05 Dainippon Sumitomo Pharma Co., Ltd. Fine particulate preparation comprising complex of nucleic acid molecule and collagen
US7838502B2 (en) * 2005-05-06 2010-11-23 University Of Massachusetts Medical School Compositions and methods to modulate H. influenzae pathogenesis
WO2006126600A1 (ja) * 2005-05-25 2006-11-30 National University Corporation Nagoya Universtiy 血管閉塞性疾患用医薬組成物
US8029990B2 (en) * 2005-07-22 2011-10-04 Koken Co., Ltd. Cell transfection array for introduction of nucleic acid
WO2007107774A2 (en) * 2006-03-22 2007-09-27 Cartela R & D Ab Integrin alpha-10 subunit as therapeutic target and diagnostic/prognostic marker for cancer
EP2127681A4 (en) * 2007-02-16 2011-10-12 Anges Mg Inc THERAPEUTIC AGENT AGAINST PARODONTAL DISEASES AND ALVEOLAR BONE LOSS THROUGH OPERATION
JP5789927B2 (ja) * 2010-07-30 2015-10-07 Jnc株式会社 放射線照射コラーゲン様ペプチドを用いた核酸導入法
WO2013102878A2 (en) 2012-01-05 2013-07-11 Department Of Biotechnology (Dbt) Fat1 gene in cancer and inflammation
US20220331405A1 (en) * 2019-08-30 2022-10-20 University Of Florida Research Foundation, Inc. Aptamer assemblies for protein crosslinking
WO2022120338A1 (en) * 2020-12-03 2022-06-09 University Of Florida Research Foundation, Inc. Aptamer assemblies for protein crosslinking

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5115094B2 (zh) * 1972-11-01 1976-05-14
JPH0712375B2 (ja) * 1986-11-17 1995-02-15 株式会社高研 移植組成物及びその製造方法
US5069936A (en) * 1987-06-25 1991-12-03 Yen Richard C K Manufacturing protein microspheres
JPS6416581A (en) 1987-07-09 1989-01-20 Rikagaku Kenkyusho Frozen animal cell and production thereof
JPH01157388A (ja) 1987-12-11 1989-06-20 Mitsubishi Heavy Ind Ltd 形質転換方法
US5078997A (en) * 1988-07-13 1992-01-07 Cetus Corporation Pharmaceutical composition for interleukin-2 containing physiologically compatible stabilizers
US5098890A (en) * 1988-11-07 1992-03-24 Temple University-Of The Commonwealth System Of Higher Education Antisence oligonucleotides to c-myb proto-oncogene and uses thereof
US5936035A (en) 1988-11-21 1999-08-10 Cohesion Technologies, Inc. Biocompatible adhesive compositions
US5614587A (en) * 1988-11-21 1997-03-25 Collagen Corporation Collagen-based bioadhesive compositions
JP3187410B2 (ja) 1989-08-10 2001-07-11 住友製薬株式会社 脳内投与用徐放性製剤
JP2789115B2 (ja) 1989-09-07 1998-08-20 株式会社高研 可溶性コラーゲンパウダーを担体とする粒状医薬徐放剤の製造方法
CA2071989C (en) 1989-12-22 1999-07-27 Scott C. Chappel Endogenous gene expression modification with regulatory element
US5542935A (en) * 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
JP2666535B2 (ja) 1990-08-07 1997-10-22 東洋紡績株式会社 大腸菌のコンピテントセル化緩衝液および大腸菌のコンピテントセル化方法
FR2694895B1 (fr) * 1992-08-20 1994-11-10 Coletica Procédé de fabrication de microparticules en émulsion par modification de la composition chimique de la phase dispersée après émulsification.
US5646042A (en) * 1992-08-26 1997-07-08 Ribozyme Pharmaceuticals, Inc. C-myb targeted ribozymes
WO1994028014A2 (en) * 1993-05-28 1994-12-08 Chiron Corporation Peptide inhibitors of urokinase receptor activity
ATE197124T1 (de) * 1993-09-09 2000-11-15 Schering Ag Wirkstoffe und gas enthaltende mikropartikel
CA2140053C (en) * 1994-02-09 2000-04-04 Joel S. Rosenblatt Collagen-based injectable drug delivery system and its use
US5942496A (en) 1994-02-18 1999-08-24 The Regent Of The University Of Michigan Methods and compositions for multiple gene transfer into bone cells
US5583034A (en) * 1994-02-22 1996-12-10 La Jolla Institute For Allergy And Immunology Enhancement of adoptosis using antisense oligonucleotides
US5844107A (en) * 1994-03-23 1998-12-01 Case Western Reserve University Compacted nucleic acids and their delivery to cells
US5563255A (en) * 1994-05-31 1996-10-08 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
WO1996000295A1 (en) * 1994-06-27 1996-01-04 The Johns Hopkins University Targeted gene delivery system
NO180167C (no) * 1994-09-08 1997-02-26 Photocure As Fotokjemisk fremgangsmåte til å innföre molekyler i cellers cytosol
GB9422495D0 (en) 1994-11-08 1995-01-04 Medical Res Council DNA transfer method
EP0844004B1 (en) 1995-07-03 2007-09-12 Koken Co., Ltd. Collagen containing gene preparations
JP3867160B2 (ja) 1995-07-03 2007-01-10 大日本住友製薬株式会社 遺伝子製剤
US6998268B2 (en) * 1995-07-03 2006-02-14 Dainippon Sumitomo Pharma Co. Ltd. Gene preparations
EP0859636A4 (en) 1995-10-23 2002-05-02 Hyal Pharmaceutical Australia HYALURONIC ACID USED AS A DNA CARRIER FOR GENE THERAPY AND ANTI-SENSE DNA OF THE VASCULAR ENDOTHELIUM GROWTH FACTOR FOR THE TREATMENT OF ABNORMAL RETINA VASCULARIZATION
US6472204B1 (en) 1995-11-13 2002-10-29 Kiyozo Asada Methods for retroviral mediated gene transfer employing molecules, or mixtures thereof, containing retroviral binding domains and target cell binding domains
PT2111876E (pt) * 1995-12-18 2011-12-23 Angiodevice Internat Gmbh Composições de polímero reticulado e seus métodos de utilização
JP2000506865A (ja) * 1996-03-14 2000-06-06 ジ イミューン リスポンス コーポレイション インターフェロンをコードする遺伝子の標的を定めた送達
US5874006A (en) * 1996-10-31 1999-02-23 Matrix Pharmaceutical, Inc. Aseptic collagen concentration process
US6042820A (en) * 1996-12-20 2000-03-28 Connaught Laboratories Limited Biodegradable copolymer containing α-hydroxy acid and α-amino acid units
US6218112B1 (en) * 1996-12-23 2001-04-17 Cobra Therapeutics Limited Optimization of gene delivery and gene delivery system
US6524613B1 (en) * 1997-04-30 2003-02-25 Regents Of The University Of Minnesota Hepatocellular chimeraplasty
IT1293088B1 (it) 1997-07-10 1999-02-11 Isi Ist Sierovaccinogeno Ital Microparticelle per il rilascio controllato di molecole biologicamente attive e loro uso in terapia, profilassi e diagnostica in vitro e in
JPH11127843A (ja) 1997-10-27 1999-05-18 Sumitomo Bakelite Co Ltd 培養用着色容器
TW572758B (en) 1997-12-22 2004-01-21 Sumitomo Pharma Type 2 helper T cell-selective immune response inhibitors comprising purine derivatives
AU2868099A (en) * 1998-02-13 1999-08-30 Selective Genetics, Inc. Concurrent flow mixing methods and apparatuses for the preparation of gene therapy vectors and compositions prepared thereby
WO1999061063A1 (fr) 1998-05-22 1999-12-02 Sumitomo Pharmaceuticals Company, Limited Preparations geniques stables
JP3587438B2 (ja) 1999-01-14 2004-11-10 住友ベークライト株式会社 培養細胞凍結用マルチウェルプレート
JP3557924B2 (ja) * 1998-12-10 2004-08-25 トヨタ自動車株式会社 電動機制御装置及び電動機制御方法
TR199901199A3 (tr) 1999-05-31 2001-09-21 Kocagoez Tanil Bakteri transformasyon kiti
JP2001199903A (ja) 1999-11-09 2001-07-24 Eizo Mori 核酸含有複合体
EP1274410A2 (en) * 2000-03-31 2003-01-15 Trustees Of Boston University Use of locally applied dna fragments
JP2001335512A (ja) 2000-05-23 2001-12-04 Yamanouchi Pharmaceut Co Ltd 遺伝子導入のための微粒子
AU2001264317A1 (en) 2000-06-20 2002-01-02 Koken Co., Ltd. Preparations for oligonucleotide transfer
JP2002325572A (ja) 2000-12-25 2002-11-12 Univ Osaka 外来物質の導入方法
DE60232149D1 (de) 2001-06-20 2009-06-10 Dainippon Sumitomo Pharma Co Verfahren zur förderung des nukleinsäuretransfers
JP4022614B2 (ja) 2002-03-25 2007-12-19 国立大学法人大阪大学 新規なバイオビーズの作製方法
ITMI20021444A1 (it) 2002-07-01 2004-01-02 Danieli Off Mecc Tubo forma spire
US7148342B2 (en) * 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
JP4754216B2 (ja) * 2002-09-04 2011-08-24 ノバルティス アーゲー ｄｓＲＮＡ投与による神経疾患の処置
WO2004026343A1 (ja) * 2002-09-20 2004-04-01 Sumitomo Phamaceuticals Co., Ltd. 部位特異的遺伝子変換促進剤および遺伝子疾患治療剤
CA2504926C (en) * 2002-11-01 2014-01-14 The Trustees Of The University Of Pennsylvania Compositions and methods for sirna inhibition of hif-1 alpha
JP2007524349A (ja) * 2003-01-16 2007-08-30 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア ＩＣＡＭ−１のｓｉＲＮＡ阻害のための組成物及び方法
US8227434B1 (en) * 2003-11-04 2012-07-24 H. Lee Moffitt Cancer Center & Research Institute, Inc. Materials and methods for treating oncological disorders
CN1946734B (zh) * 2004-02-26 2012-07-18 贝勒研究院 系统性治疗关节炎的组合物和方法
DK1799269T3 (en) * 2004-09-28 2016-10-03 Quark Pharmaceuticals Inc Oligoribonucleotides and methods of use thereof for treating alopecia, acute renal failure, and other diseases
WO2006042396A1 (en) * 2004-10-22 2006-04-27 Universite Laval Modulation of neuroglia-derived bdnf in the treatment and prevention of pain
US7585848B2 (en) * 2005-01-11 2009-09-08 Rush University Medical Center Methods and compositions for treating, inhibiting and reversing disorders of the intervertebral disc
EP1983823A1 (en) * 2006-01-17 2008-10-29 VIB vzw Inhibitors of prolyl-hydroxylase 1 for the treatment of skeletal muscle degeneration
US8106024B2 (en) * 2006-06-16 2012-01-31 Taisho Pharmaceutical Co., Ltd. Method of treating cancer with an RPN2 gene expression inhibitor
JP2009544281A (ja) * 2006-07-21 2009-12-17 サイレンス・セラピューティクス・アーゲー プロテインキナーゼ３の発現を阻害するための手段
WO2008028085A2 (en) * 2006-08-30 2008-03-06 The Board Of Trustees Of The University Of Illinois Modulation of mlck-l expression and uses thereof
EP2069501A2 (en) * 2006-10-02 2009-06-17 Aprea Ab Rna interference against wrap53 to treat hyperproliferative diseases
US7812002B2 (en) * 2007-03-21 2010-10-12 Quark Pharmaceuticals, Inc. Oligoribonucleotide inhibitors of NRF2 and methods of use thereof for treatment of cancer
US8227444B2 (en) * 2009-12-04 2012-07-24 Opko Ophthalmics, Llc Compositions and methods for inhibition of VEGF

Also Published As

Publication number Publication date
WO2003000297A1 (fr) 2003-01-03
PT1407787E (pt) 2009-07-07
JP4081436B2 (ja) 2008-04-23
CN1622831A (zh) 2005-06-01
CA2451603A1 (en) 2003-01-03
EP1407787A4 (en) 2006-02-08
KR20040023622A (ko) 2004-03-18
ATE429930T1 (de) 2009-05-15
JPWO2003000297A1 (ja) 2005-04-07
ES2324525T3 (es) 2009-08-10
US8742091B2 (en) 2014-06-03
US20040266004A1 (en) 2004-12-30
KR100888566B1 (ko) 2009-03-12
DE60232149D1 (de) 2009-06-10
EP1407787A1 (en) 2004-04-14
CA2451603C (en) 2012-07-10
CN1313158C (zh) 2007-05-02
EP1407787B1 (en) 2009-04-29
US20100081202A1 (en) 2010-04-01

Similar Documents

Publication Publication Date Title
DK1407787T3 (da) Fremgangsmåde til fremme af nukleinsyreoverförsel
JP6986103B2 (ja) 高スループット単一細胞トランスクリプトームライブラリーならびにその作製方法および使用方法
Cheema et al. Mechanical signals and IGF‐I gene splicing in vitro in relation to development of skeletal muscle
RU2688485C2 (ru) Способы получения библиотек двухцепочечных днк и способы секвенирования для идентификации метилированных цитозинов
CA2501280C (en) Cell culture
Jafary et al. Osteoblast differentiation on collagen scaffold with immobilized alkaline phosphatase
Herbert et al. Chicken double-stranded RNA adenosine deaminase has apparent specificity for Z-DNA.
US7361493B1 (en) Production of urokinase in a three-dimensional cell culture
CA2908690A1 (en) Methods and apparatus for synthesizing nucleic acids
US6969584B2 (en) Combinatorial enzymatic complexes
Deegan et al. The developmental origins of sex-biased expression in cardiac development
Rood et al. Genomic organization and chromosome localization of the human cathepsin K gene (CTSK)
Haudenschild et al. Differential expression of multiple genes during articular chondrocyte redifferentiation
Kunitomi et al. Improved Sendai viral system for reprogramming to naive pluripotency
Robinson et al. MKK4 and metastasis suppression: a marriage of signal transduction and metastasis research
GB2409274A (en) Trap-tagging: a novel method for the identification and purification of RNA-protein complexes
Yamaguchi et al. Cloning and expression of cDNA encoding a human ubiquitin-conjugating enzyme similar to the Drosophila bendless gene product
Alntara et al. Extracellular cyclic AMP-phosphodiesterase accelerates differentiation in Dictyostelium discoideum
Helland et al. Properties and mechanism of action of eukaryotic 3-methyladenine-DNA glycosylases
Weinstein et al. Membrane and other biochemical effects of the phorbol esters and their relevance to tumor promotion
DE60226592D1 (de) Desoxycytidinkinase-mutanten mit erweiterter enzymaktivität
CN105925706B (zh) 长链非编码rna loc100506530的应用
Tanaka et al. Effect of the growth state on protein turnover in two lines of cultured BHK cells
CN105886510B (zh) 长链非编码rna enst00000529841的应用
Lopp et al. 2′, 5′-oligoadenylate synthetase from a lower invertebrate, the marine sponge Geodia cydonium, does not need dsRNA for its enzymatic activity